Literature DB >> 10810001

Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor.

K Franson1, S Rössner.   

Abstract

OBJECTIVE: To study the composition of fat intake and fat-rich meals consumed during a trial in which obese subjects were treated with a lipase-inhibitor or placebo, with emphasis on food choices and eating hours.
DESIGN: Patients were instructed to record all food and drink taken for four days prior to each dietician visit. The food diaries from all scheduled 15 treatment visits were analysed for nutritional content and composition and for temporal distribution. All meals containing 25 g of fat were defined as fat-rich.
SUBJECTS: Twenty-eight women and six men, mean age 45.2 +/- 10.9 (SD) years with a mean body mass index of 37.3 +/- 3.3 (SD) kg m-2 at the beginning of the study.
RESULTS: Fat intake, both as absolute weight and as energy % was generally higher in the placebo group but no significant trend over time could be seen. Fat rich meals were increased by 59% towards the end of the study. Most fat rich meals were eaten at lunch and dinner. Cooking fat, fatty sauces, meat dishes and cheese contributed to the major proportion of fat, both for placebo and drug treated subjects. No major changes were seen in food choice over time.
CONCLUSION: A lipase inhibitor may affect the amount of fat ingested but does not seem to change major sources of fat. The typical fat-rich meal consumed by these subjects was a meat dish, consumed in the evening.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810001     DOI: 10.1046/j.1365-2796.2000.t01-1-00666.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  4 in total

1.  Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders.

Authors:  Mette Svendsen; Serena Tonstad
Journal:  Nutr J       Date:  2011-03-08       Impact factor: 3.271

2.  Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity.

Authors:  Ulf Holmbäck; Anders Forslund; Stefan Grudén; Göran Alderborn; Arvid Söderhäll; Per M Hellström; Hans Lennernäs
Journal:  Obes Sci Pract       Date:  2020-02-07

Review 3.  Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.

Authors:  Thi Thanh Binh Nguyen; Yan Yan Jin; Hea-Jong Chung; Seong-Tschool Hong
Journal:  Molecules       Date:  2017-10-24       Impact factor: 4.411

4.  Hafnia alvei HA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity.

Authors:  Nicolas Lucas; Romain Legrand; Camille Deroissart; Manon Dominique; Saïda Azhar; Marie-Anne Le Solliec; Fatima Léon; Jean-Claude do Rego; Pierre Déchelotte; Sergueï O Fetissov; Grégory Lambert
Journal:  Microorganisms       Date:  2019-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.